The addition of another potent but less selective BCL2 inhibitor (ABT-263, or navitoclax) also increased tumor cell apoptosis in vitro independent of p53 status and significantly delayed tumor growth in mice [9]. The gene discussed is TP53; the disease is neoplasm.